Publication: Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer
No Thumbnail Available
Date
2013-03-18
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Roti, Giovanni, Anne Carlton, Kenneth Ross, Michele Markstein, Kostandin Pajcini, Angela H. Su, Norbert Perrimon et al. "Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer." Cancer Cell 23, no. 3 (2013): 390-405. DOI: 10.1016/j.ccr.2013.01.015
Research Data
Abstract
Notch1 is a rational therapeutic target in several human cancers, but as a transcriptional regulator, it poses a drug discovery challenge. To identify Notch1 modulators, we performed two cell-based, high-throughput screens for small-molecule inhibitors and cDNA enhancers of a NOTCH1 allele bearing a leukemia-associated mutation. SERCA calcium channels emerged at the intersection of these complementary screens. SERCA inhibition preferentially impairs the maturation and activity of mutated Notch1 receptors and induces a G0/G1 arrest in NOTCH1-mutated human leukemia cells. A small-molecule SERCA inhibitor has on-target activity in two mouse models of human leukemia and interferes with Notch signaling in Drosophila. These studies “credential” SERCA as a therapeutic target in cancers associated with NOTCH1 mutations.
Description
Other Available Sources
Keywords
Research Subject Categories::NATURAL SCIENCES::Biology::Cell and molecular biology, Research Subject Categories::MEDICINE::Morphology, cell biology, pathology::Morphology::Tumour biology
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service